Pulse Biosciences, INC 8-K filings

Pulse Biosciences, Inc. announced the appointment of Steven T. Weber as its new Vice President of Accounting, Global Corporate Controller, and Principal Accounting Officer, effective July 14, 2025.

Pulse Biosciences reported its Q1 2025 financial results, highlighting increased costs due to expanding operations and progress in clinical trials for its nsPFA technology.

Pulse Biosciences reports positive preliminary results from its first-in-human feasibility study using Nanosecond Pulsed Field Ablation technology for the treatment of benign thyroid nodules and announces financial results for the fourth quarter and full year ended December 31, 2024.

Pulse Biosciences appoints Jon Skinner as CFO, effective February 3, 2025, to support operational excellence and commercialization of the CellFX nanosecond PFA Platform.

Pulse Biosciences reports successful treatment of atrial fibrillation in initial patients using its Nanosecond PFA 360 Cardiac Catheter, showcasing promising early results.

Pulse Biosciences provides an update on its CellFX nsPFA product development programs, including cardiac catheter, clamp, and percutaneous electrode technologies, in an investor presentation.

Paul LaViolette, current Co-Chairman of the Board, has been appointed as the new CEO of Pulse Biosciences, effective January 9, 2025, alongside the grant of inducement awards to new employees.

Pulse Biosciences will redeem a portion of its outstanding warrants after its stock price exceeded the required threshold for twenty consecutive trading days.

Pulse Biosciences CEO Burke T. Barrett has resigned, effective December 6, 2024, with the company's development plans remaining on track.

Pulse Biosciences' Co-Chairman, Robert W. Duggan, is evaluating a potential market purchase of up to 500,000 shares of the company's common stock by December 10, 2024.

Pulse Biosciences reports successful early results from a study using its nano-PFA technology to treat benign thyroid nodules, showing significant volume reduction and symptom relief.

Pulse Biosciences reported its third quarter 2024 financial results and announced the appointment of a new Chief Medical Officer of Electrophysiology, along with a new medical advisor.

Pulse Biosciences has released an updated investor presentation detailing progress on its CellFX nsPFA product development programs.

Pulse Biosciences appoints Paul LaViolette as Co-Chairman, reports progress in clinical trials, and announces preliminary Q2 2024 financial results.

Pulse Biosciences reports successful treatment of the first two patients in a feasibility study using its novel Cardiac Surgery System for atrial fibrillation, and enrollment in the FDA's TAP program.

Pulse Biosciences has entered into an agreement to sell up to $60 million of its common stock through an at-the-market offering and has released preliminary unaudited financial results for the second quarter of 2024.

Pulse Biosciences has been granted Breakthrough Device Designation by the FDA for its CellFX nsPFA Cardiac Surgery System, aimed at treating atrial fibrillation.

Pulse Biosciences successfully closed its rights offering, raising $60 million with significant oversubscription, to support the development of its CellFX nsPFA technology.

Pulse Biosciences successfully completed its rights offering, generating $60 million in gross proceeds and potentially an additional $66 million from warrant exercises.

Pulse Biosciences held its 2024 Annual Meeting of Stockholders, electing five directors and ratifying the appointment of Deloitte & Touche LLP as its independent auditor.

Pulse Biosciences has commenced a rights offering to raise up to $60 million by offering units to existing shareholders.

Pulse Biosciences has announced a revised record date of May 31, 2024, for its rights offering, targeting up to $60 million in gross proceeds.

Pulse Biosciences has appointed Burke T. Barrett as its new CEO, while Kevin Danahy transitions to Chief Commercial Officer to lead the commercialization of the CellFX nsPFA system.

Pulse Biosciences has successfully completed the first U.S. procedure using its CellFX nsPFA Percutaneous Electrode System for soft tissue ablation.

Pulse Biosciences reported its Q1 2024 financial results, highlighted by FDA clearance for its CellFX nsPFA Percutaneous Electrode and a planned $60 million rights offering.

Pulse Biosciences has set the record date for its rights offering, aiming to raise up to $60 million through the sale of units consisting of common stock and warrants.

Pulse Biosciences reported its 2023 financial results and announced a rights offering to raise up to $60 million.

Pulse Biosciences has received FDA 510(k) clearance for its CellFX nsPFA Percutaneous Electrode System, marking a significant milestone for the company's surgical applications.

Pulse Biosciences reports favorable 60-day follow-up data from initial patients in its CellFX nsPFA cardiac catheter study, showing promising results for atrial fibrillation treatment.